10 reasons to use naproxen for infections Review article
Article Sidebar
Published:
Dec 1, 2024
Keywords:
naproxen, mechanism of action, therapy
Main Article Content
Abstract
Naproxen is a nonsteroidal anti-inflammatory, analgesic, and antipyretic drug whose primary mechanism of action is based on inhibiting prostaglandin synthesis. The drug is effective in combating pain of various etiologies, especially in the treatment of rheumatoid arthritis. In a different mechanism, it exerts a direct antiviral effect, it also supports the treatment of bacterial infections, and the ability to deposition at the site of inflammation is important. The paper discusses the wide therapeutic options that distinguish naproxen from other nonsteroidal anti-inflammatory.
Article Details
How to Cite
Sapilak, B. J. (2024). 10 reasons to use naproxen for infections. Medycyna Faktow (J EBM), 17(3(64), 384-390. https://doi.org/10.24292/01.MF.0324.11
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553): 1302-8.
2. Sękowska A. 10 powodów, dla których warto stosować naproksen w świetle nowych doniesień naukowych. Medycyna Faktów. 2021; 4(53): 400-7. https://doi.org/10.24292/01.MF.0421.8.
3. Zhang H, Wu Y, Lin Z et al. Naproxen for the treatment of neoplastic fever: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(22): e15840. http://doi.org/10.1097/MD.0000000000015840.
4. Chang JC. Antipyretic effect of naproxen and corticosteroids on neoplastic fever. J Pain Symptom Manage. 1988; 3: 141-4.
5. Coskun O, Karakaş A, Savaşci U et al. The value of naproxen test as a diagnostic method to differentiate cause of fever. Taf Preventive Medicine Bulletin. 2012; 11: 779-82.
6. Unger M, Karanikas G, Kerschbaumer A et al. Fever of unknown origin (FUO) revised. Wien Klin Wochenschr. 2016; 128(21-22): 796-801.
7. Cetin II, Ekici F, Kocabas A et al. The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen. Turk J Pediatr. 2016; 58(5): 473-9. http://doi.org/10.24953/turkjped.2016.05.003.390.
8. Cashman TM, Starns RJ, Johnson J et al. Comparative effects of naproxen and aspirin on fever in children. J Pediatr. 1979; 95(4): 626-9. http://doi.org/10.1016/s0022-3476(79)80784-2.
9. Paglia MDG, Silva MT, Lopes LC et al. Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. PLoS One. 2021; 16(4): e0248866. http://doi.org/10.1371/journal.pone.0248866.
10. Tarp S, Bartels EM, Bliddal H et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2012; 64(11): 3511-21. http://doi.org/10.1002/art.34644. PMID: 22833186.
11. Ozdol C, Gulec S, Rahimov U et al. Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention. Thromb Res. 2007; 119(4): 453-9. http://doi.org/10.1016/j.thromres.2006.11.003.
12. Woroń J, Wordliczek J. Farmakoterapia gorączki – jeżeli NLPZ to który, czyli dlaczego naproksen. Terapia. 2019; 12: 38-40.
13. Dilly S, Fotso A, Lejal N et al. From naproxen repurposing to naproxen analogues and their antiviral activity against influenza A virus. J Med Chem. 2018; 61: 7202-17.
14. Zheng W, Fan W, Zhang S et al. Naproxen exhibits broad anti-influenza virus activity in mice by impending viral nucleoprotein nuclear export. Cell Rep. 2019; 27: 1875-85.
15. Cao L, She Z, Zhao Y et al. Inhibition of RAN attenuates influenza a virus replication and nucleoprotein nuclear export. Emerg Microbes Infect. 2024; 13(1): 2387910. http://doi.org/10.1080/22221751.2024.2387910.
16. Robb CT, Goepp M, Rossi AG et al. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br J Pharmacol. 2020; 177(21): 4899-920. http://doi.org/10.1111/bph.15206.
17. Hung IFN, To KKW, Chan JFW et al. Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial. Chest. 2017; 151: 1069-80.
18. Chiou WC, Hsu MS, Chen YT et al. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. J Enzyme Inhib Med Chem. 2021; 36(1): 147-53.
19. Khodavirdipour A. Inclusion of Cephalexin in COVID-19 Treatment Combinations May Prevent Lung Involvement in Mild Infections: A Case Report with Pharmacological Genomics Perspective. Glob Med Genet. 2021; 8(2): 78-81. http://doi.org/10.1055/s-0041-1726461.
20. Al-Horani RA, Kar S. Potential Anti-SARS-CoV-2 Therapeutics That Target the PostEntry Stages of the Viral Life Cycle: A Comprehensive Review. Viruses. 2020; 12(10): 1092. http://doi.org/10.3390/v12101092.
21. bbKiani P, Scholey A, Dahl TA et al. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. Viruses. 2021; 13(4): 558. http://doi.org/10.3390/v13040558.
22. Asadi M, Sayar S, Radmanesh E et al. Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial. Diabetes Metab Syndr. 2021; 15(6): 102319. http://doi.org/10.1016/j.dsx.2021.102319.
23. Terrier O, Dilly S, Pizzorno A et al. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. Molecules. 2021; 26(9): 2593. http://doi.org/10.3390/molecules26092593.
24. Castro VM, Ross RA, McBride SM et al. Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records. MedRxiv. 2020: 20061994.
25. Prozzi GR, Cañás M, Urtasun MA et al. Riesgo cardiovascular de los antiinflamatorios no esteroideos [Cardiovascular risk of non-steroidal anti-inflammatory drugs]. Medicina (B Aires). 2018; 78(5): 349-55.
26. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382: 769-79.
27. Woroń J. Miejsce naproksenu w farmakoterapii bólu i gorączki. Co wiemy w 2022 roku? Medycyna Faktów. 2022; 4(57): 401-3. https://doi.org/10.24292/01.MF.0422.4.
2. Sękowska A. 10 powodów, dla których warto stosować naproksen w świetle nowych doniesień naukowych. Medycyna Faktów. 2021; 4(53): 400-7. https://doi.org/10.24292/01.MF.0421.8.
3. Zhang H, Wu Y, Lin Z et al. Naproxen for the treatment of neoplastic fever: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(22): e15840. http://doi.org/10.1097/MD.0000000000015840.
4. Chang JC. Antipyretic effect of naproxen and corticosteroids on neoplastic fever. J Pain Symptom Manage. 1988; 3: 141-4.
5. Coskun O, Karakaş A, Savaşci U et al. The value of naproxen test as a diagnostic method to differentiate cause of fever. Taf Preventive Medicine Bulletin. 2012; 11: 779-82.
6. Unger M, Karanikas G, Kerschbaumer A et al. Fever of unknown origin (FUO) revised. Wien Klin Wochenschr. 2016; 128(21-22): 796-801.
7. Cetin II, Ekici F, Kocabas A et al. The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen. Turk J Pediatr. 2016; 58(5): 473-9. http://doi.org/10.24953/turkjped.2016.05.003.390.
8. Cashman TM, Starns RJ, Johnson J et al. Comparative effects of naproxen and aspirin on fever in children. J Pediatr. 1979; 95(4): 626-9. http://doi.org/10.1016/s0022-3476(79)80784-2.
9. Paglia MDG, Silva MT, Lopes LC et al. Use of corticoids and non-steroidal anti-inflammatories in the treatment of rheumatoid arthritis: Systematic review and network meta-analysis. PLoS One. 2021; 16(4): e0248866. http://doi.org/10.1371/journal.pone.0248866.
10. Tarp S, Bartels EM, Bliddal H et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2012; 64(11): 3511-21. http://doi.org/10.1002/art.34644. PMID: 22833186.
11. Ozdol C, Gulec S, Rahimov U et al. Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention. Thromb Res. 2007; 119(4): 453-9. http://doi.org/10.1016/j.thromres.2006.11.003.
12. Woroń J, Wordliczek J. Farmakoterapia gorączki – jeżeli NLPZ to który, czyli dlaczego naproksen. Terapia. 2019; 12: 38-40.
13. Dilly S, Fotso A, Lejal N et al. From naproxen repurposing to naproxen analogues and their antiviral activity against influenza A virus. J Med Chem. 2018; 61: 7202-17.
14. Zheng W, Fan W, Zhang S et al. Naproxen exhibits broad anti-influenza virus activity in mice by impending viral nucleoprotein nuclear export. Cell Rep. 2019; 27: 1875-85.
15. Cao L, She Z, Zhao Y et al. Inhibition of RAN attenuates influenza a virus replication and nucleoprotein nuclear export. Emerg Microbes Infect. 2024; 13(1): 2387910. http://doi.org/10.1080/22221751.2024.2387910.
16. Robb CT, Goepp M, Rossi AG et al. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br J Pharmacol. 2020; 177(21): 4899-920. http://doi.org/10.1111/bph.15206.
17. Hung IFN, To KKW, Chan JFW et al. Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial. Chest. 2017; 151: 1069-80.
18. Chiou WC, Hsu MS, Chen YT et al. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. J Enzyme Inhib Med Chem. 2021; 36(1): 147-53.
19. Khodavirdipour A. Inclusion of Cephalexin in COVID-19 Treatment Combinations May Prevent Lung Involvement in Mild Infections: A Case Report with Pharmacological Genomics Perspective. Glob Med Genet. 2021; 8(2): 78-81. http://doi.org/10.1055/s-0041-1726461.
20. Al-Horani RA, Kar S. Potential Anti-SARS-CoV-2 Therapeutics That Target the PostEntry Stages of the Viral Life Cycle: A Comprehensive Review. Viruses. 2020; 12(10): 1092. http://doi.org/10.3390/v12101092.
21. bbKiani P, Scholey A, Dahl TA et al. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. Viruses. 2021; 13(4): 558. http://doi.org/10.3390/v13040558.
22. Asadi M, Sayar S, Radmanesh E et al. Efficacy of naproxen in the management of patients hospitalized with COVID-19 infection: A randomized, double-blind, placebo-controlled, clinical trial. Diabetes Metab Syndr. 2021; 15(6): 102319. http://doi.org/10.1016/j.dsx.2021.102319.
23. Terrier O, Dilly S, Pizzorno A et al. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. Molecules. 2021; 26(9): 2593. http://doi.org/10.3390/molecules26092593.
24. Castro VM, Ross RA, McBride SM et al. Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health records. MedRxiv. 2020: 20061994.
25. Prozzi GR, Cañás M, Urtasun MA et al. Riesgo cardiovascular de los antiinflamatorios no esteroideos [Cardiovascular risk of non-steroidal anti-inflammatory drugs]. Medicina (B Aires). 2018; 78(5): 349-55.
26. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382: 769-79.
27. Woroń J. Miejsce naproksenu w farmakoterapii bólu i gorączki. Co wiemy w 2022 roku? Medycyna Faktów. 2022; 4(57): 401-3. https://doi.org/10.24292/01.MF.0422.4.